IMPORTANT: Beginning at 8:00 AM on July 22, Temple University Hospital – Main Campus (Broad and Ontario Streets) will no longer provide Labor and Delivery services. All childbirth services will be relocated to our new hospital location.

800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2)

view all Clinical Trials

Overview

The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.

Clinical Trial Information

Protocol

NCT05614063 IRB#: 30876

Phase

3

Condition(s)

Focal Onset Seizures

Investigator

Mercedes P. Jacobson, MD, Valeriya Poukas, MD and Avani A. Shah, MD

Coordinator

Kathleen Hatala, RN, BSN
215-707-4171

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, call 215-707-4171 or email [email protected].

Full Title

A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures